Literature DB >> 26728671

Quality of life and survival after II stage nonsmall cell carcinoma surgery: Video-assisted thoracic surgery versus thoracotomy lobectomy.

J Zhao, Y Zhao, T Qiu, W Jiao1, Y Xuan, X Wang, Y Wang, Y Luo.   

Abstract

PURPOSE: Due to the improvement of thoracoscopic technology and surgeon's ability, plenty of nonsmall cell lung cancer (NSCLC) was treated by video-assisted thoracic surgery (VATS). This study was designed to evaluate the quality of life (QOL) and survival in II stage NSCLC patients following lobectomy, comparing VATS with thoracotomy.
METHODS: Between 2010 and 2012, 217 II stage NSCLC patients (VATS: 114 patients, OPEN: 103 patients) were enrolled in a long-standing, prospective observational lung cancer surgery outcomes study. Short-form 36 health survey (SF-36) and time to progression (TTP) were measured to evaluate the QOL and postoperative survival.
RESULTS: There were significant differences between the two groups in the preoperative radiation therapy and differentiation, and the VATS group had less postoperative complication, blood loss, intraoperative fluid administration, and shorter length of stay. Statistical analysis of SF-36 questionnaire revealed that VATS group score was higher on seven health dimensions: Bodily pain (BP), energy (EG), general health, physical functioning, mental health, SF, and role-physical (RP), but only BP, EG, and RP have statistical significance. Using survival analysis, there was no significant difference between VATS and OPEN group, in which the mean TTP of VATS group is 18.5 months, while OPEN group is 20 months.
CONCLUSIONS: VATS lobectomy tends to score higher on the QOL and functioning scales and has equivalent postsurgical survival compared with OPEN lobectomy for II stage nonsmall cell carcinoma patients.

Entities:  

Mesh:

Year:  2015        PMID: 26728671     DOI: 10.4103/0019-509X.172510

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  7 in total

Review 1.  ERAS and patient reported outcomes in thoracic surgery: a review of current data.

Authors:  Rachel L Medbery; Felix G Fernandez; Onkar V Khullar
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

2.  Factors Associated With New Persistent Opioid Usage After Lung Resection.

Authors:  Alexander A Brescia; Caitlin A Harrington; Alyssa A Mazurek; Sarah T Ward; Jay S J Lee; Hsou Mei Hu; Chad M Brummett; Jennifer F Waljee; Pooja A Lagisetty; Kiran H Lagisetty
Journal:  Ann Thorac Surg       Date:  2018-10-11       Impact factor: 4.330

3.  Thoracic surgeon and patient focus groups on decision-making in early-stage lung cancer surgery.

Authors:  Rebecca M Schwartz; Ksenia Gorbenko; Samantha M Kerath; Raja Flores; Sheila Ross; Tonya N Taylor; Emanuela Taioli; Claudia Henschke
Journal:  Future Oncol       Date:  2017-12-12       Impact factor: 3.404

Review 4.  Patient-Reported Outcomes in Cardiothoracic Surgery.

Authors:  Melanie Subramanian; Benjamin D Kozower; Lisa M Brown; Onkar V Khullar; Felix G Fernandez
Journal:  Ann Thorac Surg       Date:  2019-01       Impact factor: 4.330

5.  Comparison of costs of hospitalization of patients with primary lung cancer after lobectomy with access through classic thoracotomy and VATS in the conditions of financing based on diagnosis-related groups.

Authors:  Joanna Lipińska; Marcin Wawrzycki; Sławomir Jabłoński
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

6.  Comparative Effectiveness of Surgical Approaches for Lung Cancer.

Authors:  Adwaiy Manerikar; Melissa Querrey; Emily Cerier; Samuel Kim; David D Odell; Lorenzo L Pesce; Ankit Bharat
Journal:  J Surg Res       Date:  2020-12-09       Impact factor: 2.417

Review 7.  Effect of operative approach on quality of life following anatomic lung cancer resection.

Authors:  Emily S Singer; Peter J Kneuertz; Jennifer Nishimura; Desmond M D'Souza; Ellen Diefenderfer; Susan D Moffatt-Bruce; Robert E Merritt
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.